183 related articles for article (PubMed ID: 37462865)
1. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.
Zhang B; Zhao R; Wang Q; Zhang YJ; Yang L; Yuan ZJ; Yang J; Wang QJ; Yao L
Adv Ther; 2023 Oct; 40(10):4339-4357. PubMed ID: 37462865
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
3. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
4. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
5. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
[TBL] [Abstract][Full Text] [Related]
6. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
7. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments.
Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J
J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606
[TBL] [Abstract][Full Text] [Related]
9. An EMT-related genes signature as a prognostic biomarker for patients with endometrial cancer.
Yu Y; Zhang Y; Li Z; Dong Y; Huang H; Yang B; Zhao E; Chen Y; Yang L; Lu J; Qiu F
BMC Cancer; 2023 Sep; 23(1):879. PubMed ID: 37723477
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
11. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
12. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
13. Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.
Hu Y; Zou D
PLoS One; 2021; 16(12):e0260811. PubMed ID: 34965257
[TBL] [Abstract][Full Text] [Related]
14. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer.
Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G
Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794
[TBL] [Abstract][Full Text] [Related]
15. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.
Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H
Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154
[TBL] [Abstract][Full Text] [Related]
16. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
Yan C; Liu Q; Jia R
Front Oncol; 2022; 12():829045. PubMed ID: 35186763
[TBL] [Abstract][Full Text] [Related]
17. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
Zhang Z; Zheng S; Lin Y; Sun J; Ding N; Chen J; Zhong J; Shi L; Xue M
BMC Cancer; 2020 Nov; 20(1):1135. PubMed ID: 33228590
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
19. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
20. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
